North Carolina Chinese Business Association (NCCBA) to Present Seminar “Beyond the Horizon” The Application of Nanotechnology in Personalized MedicinePost by: RJ Lee Group News
- 3:33PM Jun 14, 2011
- Comments off
Nanotechnology and Personalized Medicine are two of the most rapidly developing areas of biomedical research and the most promising technologies for improving healthcare and human life.
Dr. Lin Wu, Director of Biotechnology and Pharmaceutical Services at RJ Lee Group Inc., Monroeville, PA and one of the founding trustees of NCCBA will be the featured speaker in this NCCBA Leadership Speakers Series seminar. Dr. Wu will discuss one of the most active application areas of nanotechnology – nanomedicine – the application of nanotechnology to the medical advancement of therapeutics and diagnostics. He will relate his personal view on the potential applications of nanotechnology and personalized medicine as well as his recent return to the life science industry (RJ Lee Group Inc.) attracted by the firm’s nano-technological potential. He will share his personal journey, transitioning from academia to industry, from research to development, and from scientist to manager, the lessons learned, and the importance of looking beyond the horizon.
To register for this seminar, please contact: Ms. Mei Dai, firstname.lastname@example.org
Linxian (Lin) Wu, Ph.D.
Dr. Wu is a seasoned executive in the life science industries who has worked in the pharmaceutical and biological products regulatory agencies both in China (SFDA) and Canada. He received his Ph.D. in Medical Microbiology and Infectious Diseases from University of Alberta, Canada and performed post-doctoral training in Molecular Virology at the Medical College of Pennsylvania. His industrial experience involves the areas of clinical diagnostics, therapeutic medical devices, and pharmaceuticals. He was Director of Research & Development at GenTrak Inc. (Philadelphia, Pa.); Executive Vice President and Chief Technology Officer at Gull Laboratories, Inc. (Salt Lake City, Utah), President and Chief Operating Officer at Fresenius Hemocare Inc. (Redmond, Wash.); and President and Chief Operating Officer at Fresenius Kabi Clayton LP (Clayton, N.C.). Currently Dr. Wu is the Director of Biotechnology and Pharmaceutical Services at RJ Lee Group Inc., a leading molecular imaging and trace materials analysis technology company with headquarters in Monroeville, PA.